A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.


Updates from The Motley Fool

Latest updates on Amgen from Fool.com.  The Fool has written over 800 articles on Amgen.
Is Amgen Inc. (AMGN) a Buy?

Can the big biotech continue delivering impressive returns in the coming decade?

Amgen Stock Split History

The grandaddy of biotech has split its stock multiple times during its history.

Is Amgen Inc. a Buy?

The big biotech has promising new drugs and a huge cash stockpile. But it also faces major headwi...

3 Tough Questions for Amgen

How successful will Amgen be in the future? Its answers to these three questions provide insight.



Stock Performance

View Interactive AMGN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Amgen.
Current Price: $184.75
Prev Close: $185.99
Open: $186.31
Bid: $184.55
Ask: $186.50
Day's Range: $184.83 - $188.09
52wk Range: $163.31 - $201.23
Volume: 11,118,823
Avg Vol 2,915,058
Market Cap: $134B
P/E (ttm): 59.04
EPS (ttm): $3.15
Div & Yield: $4.60 (2.8%)

Company Rating

What our community thinks about Amgen.
CAPS Rating 4 out of 5
 
2208 Outperform
167 Underperform
CAPS All Stars
 
564 Outperform
24 Underperform

How do you think Amgen will perform against the market?



You pick for Amgen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Robert A. Bradway, CEO

77% Approve

Based on 568 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Amgen.

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers